Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

5.9K
5.9K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutagenesis Screens for Prostate Cancer Using Replication-Incompetent Lentiviral Vectors.

Methods in molecular biology (Clifton, N.J.)·2018
Same author

Efficacy and safety of a clinically relevant foamy vector design in human hematopoietic repopulating cells.

The journal of gene medicine·2018
Same author

Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.

Blood advances·2018
Same author

Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.

Oncotarget·2018
Same author

Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.

Biomedicines·2017
Same author

Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy.

Biomedicines·2017

Related Experiment Video

Updated: Mar 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes.

Jonah D Hocum1, Ian Linde1, Dustin T Rae1

  • 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 99210, United Sates.

Scientific Reports
|November 5, 2016
PubMed
Summary

Foamy retroviral vectors were engineered to reduce genotoxicity in gene therapy. Modified vectors integrate away from critical genes, offering a safer approach for treating genetic diseases.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector
10:13

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector

Published on: January 12, 2018

9.5K

Related Experiment Videos

Last Updated: Mar 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector
10:13

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector

Published on: January 12, 2018

9.5K

Area of Science:

  • Gene therapy
  • Retroviral vectors
  • Molecular biology

Background:

  • Retroviral gene therapy shows promise for genetic diseases but faces genotoxicity challenges.
  • Reducing integration near genes and proto-oncogenes is crucial for clinical safety.
  • Foamy retroviral vectors offer potential advantages over other retroviral vectors due to their integration profile.

Purpose of the Study:

  • To retarget foamy retroviral vectors away from genes and towards safer genomic regions.
  • To develop a clinically relevant and efficient gene therapy vector system.

Main Methods:

  • Modification of foamy retroviral Gag and Pol proteins to alter vector integration.
  • Production of retargeted foamy retroviral vectors at high titers.
  • Assessment of integration site profiles and transduction efficiency in human cord blood cells.

Main Results:

  • Retargeted foamy retroviral vectors showed significantly reduced integration near genes and proto-oncogenes (p < 0.001).
  • High titers (>10^7 transducing units/ml) of retargeted vectors were achieved without requiring engineered target cells.
  • Efficient transduction and retargeting were demonstrated in human cord blood CD34+ cells.

Conclusions:

  • Modified foamy retroviral vectors provide a safer integration profile for gene therapy applications.
  • The described Gag and Pol helper constructs enable straightforward retargeting of therapeutic foamy retroviral vectors.
  • This approach advances the clinical applicability of foamy retroviral vectors for genetic disease treatment.